Delivery Order SPE2DB22D1106-SPE2DB25FFHJ0
- Not listed
- The Defense Logistics Agency awarded a competitive delivery order valued at $1,971.30 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. The award, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed price transaction with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $2,526.12 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on September 19, 2025, with completion scheduled for September 22, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $1,389.81 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml) on September 17, 2025, with an ultimate completion date of September 18, 2025. The contract employs firm fixed pricing and was awarded competitively without set-aside provisions. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,051.36 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) on July 24, 2025, with ultimate completion scheduled for July 25, 2025. This competitively awarded, firm fixed-price delivery order is not set-aside and represents performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract operates under AmerisourceBergen Drug Corp's existing...
- The Defense Logistics Agency awarded a delivery order valued at $1,334.63 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), with a completion date of May 28, 2025. This is a firm fixed price, non-set-aside delivery order issued under a competitive award process. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in a 60 mL quantity, with a ceiling value of $1,968.69. This is a firm fixed-price delivery order with an ultimate completion date of July 23, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its...
- The Defense Logistics Agency awarded a delivery order valued at $1,283.02 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), with a completion date of July 31, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price pricing and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreements. The product will be delivered to the company's headquarters in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, with a ceiling value of $3,016.29. This is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) valued at $1,740.04 under a firm fixed-price contract type. This delivery order, which has an ultimate completion date of July 31, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, valued at $1,082.52 under a firm fixed-price contract. This delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 31, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFHJ0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,286.38 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (120 mL) on September 5, 2025, with an ultimate completion date of September 8, 2025. This competitively awarded, firm fixed-price delivery order was placed without set-aside restrictions and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order is executed under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including medications, vaccines, and specialized medical devices. The DLA's strategic approach of establishing multiple regional Prime Vendor Global Program Generation V contracts positions AmerisourceBergen Drug Corp to serve diverse customers including the Defense Health Agency and U.S. Coast Guard through flexible procurement vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 9/5/25 |